Founded in 1987, Merit Medical manufactures medical devices used in interventional, diagnostic, and therapeutic procedures across radiology, cardiology, breast, vascular, and dialysis specialties. Locally, Merit Medical Australia opened for business in 2016 with an office in Melbourne, followed by an office in Auckland in 2017. Merit Medical ANZ is dedicated to supplying and supporting our customers with best-in-class innovative products, dedicated education offerings, and our commitment to social and environmental responsibility.
For more information, please visit: www.merit.com

Icon is a leading cancer care organisation with centres across Australia and globally in New Zealand, Singapore, Indonesia, Malaysia, China and the UK. We deliver integrated medical oncology, haematology, radiation oncology, molecular imaging, theranostics and clinical research, aiming to provide the best care possible close to home. Icon Cancer Centre Australia brings together 250+ specialists across 45 centres, offering multidisciplinary expertise. We provide comprehensive breast cancer treatment, including chemotherapy, hormone and targeted therapies, supported by advanced radiation techniques such as stereotactic approaches, SGRT for tattooless positioning and DIBH for improved patient outcomes. Our teams are committed to personalised, high-quality care.
LinkedIn: @Icon Cancer Centre – Australia & New Zealand
For more information, please visit: iconcancercentre.com.au/

Since 1992, Device Technologies has been dedicated to improving patients’ lives through leading edge technology and services. Successfully supplying hospitals and healthcare professionals with the finest medical solutions for their patients, we continue to grow, with over 200 trusted brands over 1000 highly skilled staff throughout Australia, New Zealand, and Asia.
Behind every brand distributed by Device Technologies is the concept that we are delivering leading technology into the most capable hands. We nurture the relationship between distributor and healthcare professionals, guiding the process from concept to delivery and ongoing support with training and technical service specialty teams.
For more information, please visit: www.device.com.au

Daiichi Sankyo, a global pharmaceutical company with corporate origins in Japan with over 120 years of innovation, is expanding its Australian presence. Our mission: to redefine cancer treatment through our proprietary antibody drug conjugate (ADC) technology, aiming to become a global top ten in oncology by 2030.
In Australia, we’re building a dedicated team, conducting 18 clinical trials at 47 sites evaluating our DXd ADCs*, and working to bring their benefits to patients sooner. Our pipeline of ADCs and novel entities targets difficult-to-treat cancers including breast, lung, gastric, ovarian, and endometrial. We are committed to partnering with researchers, clinicians, patients, patient advocates and government to deliver our mission.
*does not include other assets
For more information please visit: astrazeneca.com.au

Novartis is improving the lives of more than 2.5 million patients across Australia and New Zealand through our medicines. By partnering with the healthcare system we are working for patients to address their needs, and we are committed to accelerating patient access to life saving treatments and associated healthcare.
We are reimagining medicine by using innovative science and technology to address challenging healthcare issues and our rich research pipeline has 50+ ongoing Phase III programs. We are transforming how clinical trials are run to increase patients’ access to our industry-leading clinical trials footprint in Australia.
For more information please visit: www.novartis.com/au-en/